NASDAQ: PAHC · Specialty & Generic Drug Manufacturers
Phibro Animal Health (PAHC) fair value and price range
As of 28 Sep 2026, Faircurve's model values Phibro Animal Health (PAHC) at $34.73 a share. The stock last closed at $37.24, which puts the model's fair value 6.7% below the price. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
Revalued . Price is the close of 2 Oct 2026. Phibro Animal Health Corporation.
Faircurve Insights · 28 Sep 2026
Phibro Animal Health Corporation operates as a global entity focused on the research, production, and supply of a wide array of animal health and mineral nutrition solutions.
Faircurve's model on 28 Sep 2026 gave a fair value of $34.73 a share, which is the midpoint of 2,000 simulations. The fair value moved -0.3% since the previous run on 19 Sep 2026, which gave $34.84. The model's calibrated range over 63 trading days is $29.14 to $42.35, built from the fair value, and ranges built this way held the price 60% of the time at this horizon. The model grades the evidence behind this valuation as low, so no verdict is shown.
Faircurve's model compares Phibro Animal Health Corporation with Supernus Pharmaceuticals, Inc., Amneal Pharmaceuticals, Inc., and Lantheus Holdings, Inc. Around its last 8 earnings reports, the stock moved +1.2% on 26 Aug 2026, -23.3% on 6 May 2026, +21.0% on 4 Feb 2026, +2.2% on 5 Nov 2025, +17.8% on 27 Aug 2025, +25.7% on 7 May 2025, +11.6% on 5 Feb 2025, and +3.3% on 7 Nov 2024. The median size of these moves, ignoring direction, was 14.7%.
Written from the figures on this page for the 28 Sep 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
What price range does the model give PAHC?
The calibrated range for PAHC over 63 trading days is $29.14 to $42.35. There is no live options data for this stock, so the range is built from the fair value and calibrated weekly against realised prices (n = 4,327 past valuations, refreshed 26 Sep 2026). Ranges built this way held the price 60% of the time at this horizon.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $15.90 to $62.39. In 50% of the simulations the fair value came out above the price the model ran on.
How does PAHC compare with similar companies?
The companies in specialty & generic drug manufacturers closest to Phibro Animal Health in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| ANIP ANI Pharmaceuticals, Inc. | $72.18 | $85.27 | +18.1% | Low evidence grade |
| AMPH Amphastar Pharmaceuticals, Inc. | $25.43 | $26.29 | +3.4% | Low evidence grade |
| PCRX Pacira BioSciences, Inc. | $25.21 | $25.32 | +0.4% | Low evidence grade |
| SUPN Supernus Pharmaceuticals, Inc. | $42.38 | $42.72 | +0.8% | Fairly valued |
| COLL Collegium Pharmaceutical, Inc. | $22.02 | $29.48 | +33.9% | Low evidence grade |
| INDV Indivior Pharmaceuticals Inc | $35.71 | $36.01 | +0.8% | Low evidence grade |
| AMRX Amneal Pharmaceuticals, Inc. | $20.30 | $18.51 | -8.8% | Fairly valued |
| LNTH Lantheus Holdings, Inc. | $99.96 | $100.31 | +0.4% | Fairly valued |
All specialty & generic drug manufacturer stocks ranked by gap to fair value
When does PAHC report earnings, and how has the stock reacted?
Phibro Animal Health's next earnings report is scheduled for 4 Nov 2026. Companies can move their dates.
Options prices on 1 Oct 2026 imply a move of about 14.1% in either direction through the nearest expiry, about 49 days out, a window that includes the report. That is the size the market is pricing, not a direction.
How PAHC moved around its last 8 earnings reports
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across these 8 reports, ignoring direction, was 14.7%.
| Report date | Two session move |
|---|---|
| 26 Aug 2026 | +1.2% |
| 6 May 2026 | -23.3% |
| 4 Feb 2026 | +21.0% |
| 5 Nov 2025 | +2.2% |
| 27 Aug 2025 | +17.8% |
| 7 May 2025 | +25.7% |
| 5 Feb 2025 | +11.6% |
| 7 Nov 2024 | +3.3% |
Phibro Animal Health at a glance
Phibro Animal Health Corporation operates as a global entity focused on the research, production, and supply of a wide array of animal health and mineral nutrition solutions.
- Market value
- $1.4B
- Sector
- Healthcare
- Industry
- Specialty & Generic Drug Manufacturers
- Revenue expected, next twelve months
- $1.6B
- Consensus revenue growth, next fiscal year
- +3.8%
- Analysts with estimates
- 3
- Beta to the US market
- 0.58
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices Phibro Animal Health on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 19 Sep 2026 the model's fair value for PAHC was $34.84. As of 28 Sep 2026 it is $34.73, a change of -0.3%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Phibro Animal Health's valuation
Is Phibro Animal Health stock undervalued or overvalued?
Faircurve's model puts PAHC's fair value at $34.73 a share against a last close of $37.24, as of 28 Sep 2026. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What is PAHC's fair value?
$34.73 a share as of 28 Sep 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $15.90 to $62.39.
What price range does the model give PAHC?
$29.14 to $42.35 over 63 trading days. Ranges built this way held the price 60% of the time across 4,327 past valuations, refreshed 26 Sep 2026.
When does Phibro Animal Health report earnings next?
The next report is scheduled for 4 Nov 2026. Companies can move their dates.
How much has PAHC moved on past earnings reports?
Across its last 8 reports the median two session move was 14.7%, ignoring direction. The largest was +25.7% around the report of 7 May 2025.
How confident is the model in this valuation?
The model's evidence grade for PAHC is low. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.